A new PCT patent of Uthever™ NMN filed by Effepharm recently

by Sep 10, 2020Company news

Effepharm recently filed a new PCT patent of Uthever™ NMN . The following is the patent details.
The patent is an application of nicotinamide mononucleotide in preparation of reagent for increasing Na+- K+- ATPase level in damaged skin muscle membrane.

The invention relates to the technical field of medicine, and provides the application of nicotinamide mononucleotide in the preparation of a reagent for increasing the Na+-K+-ATPase level in the muscle membrane of damaged skin. Through UVB-induced mouse skin injury model experiments, nicotinamide mononucleotide can increase the activity of Na+-K+-ATPase in the skin, thereby maintaining the normal sodium-potassium pump that damages the skin muscle membrane; it can improve serum, skin and liver It can reduce the oxidative stress damage induced by UVB irradiation; at the same time, it can inhibit the pro-inflammatory cytokines TNF-α, IL-1β and IL-6 and increase the anti-inflammatory cytokines IκB-α, IL- The activation of 4 and IL-10 ultimately reduces the body’s inflammatory damage, thereby providing a basis for the development of NMN-related drugs, health foods or cosmetics that improve skin aging and damage, and improve the body’s antioxidant capacity.

Effepharm has taken another great step in the cause of human health and anti-aging, so that more people can benefit from Uthever™ NMN.

Related News